US 11896617
Polynucleotides encoding rituximab-resistant chimeric antigen receptors
granted A61KA61K2039/505A61K2239/38
Quick answer
US patent 11896617 (Polynucleotides encoding rituximab-resistant chimeric antigen receptors) held by Allogene Therapeutics, Inc. expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Allogene Therapeutics, Inc.
- Grant date
- Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2039/505, A61K2239/38, A61K2239/48, A61K31/7088